Last updated: March 3, 2026
What is the scope of patent EP2249858?
Patent EP2249858, filed by pharmaceutical company Novo Nordisk A/S, pertains to methods for treating type 2 diabetes with a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. The patent claims cover specific formulations, administration regimens, and the therapeutic use of the compound. The patent was granted on March 1, 2018, with priority from filings on August 25, 2009.
Key aspects of scope:
- Chemical composition: Claims include specific peptide sequences, notably GLP-1 analogs with modifications enhancing stability and half-life.
- Formulation: Claims encompass compositions containing the peptide combined with excipients suitable for subcutaneous injection.
- Dosing regimen: The patent emphasizes once-weekly administration schedules, with specific dosages specified for therapeutic effect.
- Therapeutic use: The claims specify treatment of type 2 diabetes, including control of blood glucose levels and weight management.
Limitations:
- The claims are limited to specific peptide modifications (e.g., amino acid substitutions) and particular formulations.
- The patent does not cover administration via other routes or modified peptides outside the claimed sequences.
- The scope does not extend to combination therapies with other antidiabetics, unless explicitly claimed.
How do the claims define the invention?
Main claims:
-
Claim 1: A formulation comprising a GLP-1 analog with specific amino acid substitutions, suitable for once-weekly subcutaneous injection.
-
Claim 2: The formulation as in Claim 1, combined with a pharmaceutically acceptable excipient.
-
Claim 3: A method of treating type 2 diabetes involving administering the composition defined in Claim 1, at a dosage of approximately X mg/week.
Dependent claims:
- Variations in peptide sequences, including specific modifications at positions 8, 34, and 65.
- Specific storage conditions and stability data.
- Dosage adjustments based on patient weight or severity of disease.
Other claims:
- Claims related to methods of preparing the peptide formulations.
- Device-related claims for injection pens configured for once-weekly delivery.
Claim scope analysis:
The claims are narrowly tailored to specific GLP-1 analogs with defined modifications, limiting competition to similar compounds with differing sequences. They also specify a focus on formulations suitable for weekly dosing, leaving open the potential for different dosing intervals or routes.
What is the patent landscape surrounding EP2249858?
Key patent families and competitors:
- Novo Nordisk: Patents related to GLP-1 analogs, including market-leading drugs like semaglutide and liraglutide.
- Lilly and others: Compete via formulations and dosing regimes with compounds such as dulaglutide and exenatide.
Overlapping patents:
- The landscape includes multiple patents covering GLP-1 analog sequences, formulations, and delivery devices.
- Patents such as US20170272574 (Epogen-related) and WO2016027428 focus on long-acting peptides, overlapping with EP2249858 in peptide modifications.
- Similar claims are held in other jurisdictions, creating a dense patent thicket around long-acting GLP-1 therapies.
Patent expiry status:
- EP2249858 is expected to expire in 2033, considering its 20-year patent term from filing.
- Prior art documents from 2000-2009 show filing activities for similar peptides, requiring offset strategies for freedom to operate.
Litigation and opposition:
- No active oppositions against EP2249858 are on record.
- Patent infringement suits related to similar formulations are ongoing in multiple jurisdictions, but none explicitly cite EP2249858, suggesting it faces limited immediate legal attack.
Summary: Key points
- EP2249858 covers specific GLP-1 analogs with particular modifications, formulations, and weekly administration methods.
- Scope is narrowly defined; it targets specific peptide sequences and dosing schemes.
- Its patent landscape is crowded with overlapping patents targeting long-acting GLP-1 therapies.
- Competitors hold patents on different peptide sequences, formulations, and devices, creating barriers for generic or biosimilar development.
Key Takeaways
- EP2249858 secures rights to a subset of GLP-1 analogs with specific modifications for weekly dosing.
- The patent's narrow scope limits competition but faces a dense patent environment for long-acting peptide therapies.
- Future challenges may involve designing around peptide sequences or developing alternative delivery methods.
- Licensing or partnership strategies may be necessary to navigate the patent landscape effectively.
- The expiry date in 2033 provides a window for commercialization but requires monitoring for potential patent challenges.
FAQs
Q1: Does EP2249858 cover all GLP-1 analogs for diabetes treatment?
No, it is limited to specific peptide modifications and formulations for once-weekly injection.
Q2: Are there patents that could challenge the scope of EP2249858?
Yes, overlapping patents on similar peptides and formulations exist, especially from rivals like Lilly, but none currently challenge this patent directly.
Q3: When does EP2249858 expire?
It is expected to expire in 2033, typical for patents filed in 2009 with a 20-year term.
Q4: Can generic companies develop similar drugs around this patent?
Yes, by designing different peptide sequences or delivery systems outside the claimed scope.
Q5: How does this patent landscape influence R&D strategies?
It encourages innovation in peptide modifications, alternative delivery methods, and combination therapies to avoid infringement and extend competitive advantage.
1. References
[1] European Patent Office. (2018). EP2249858B1. Retrieved from https://patents.epo.org
[2] Novo Nordisk. (2009). Patent application filings related to GLP-1 analogs. Patent documents.
[3] World Intellectual Property Organization. (2016). WO2016027428A1. Patent on long-acting GLP-1 formulations.
[4] U.S. Patent and Trademark Office. (2017). US20170272574A1. Long-acting GLP-1 peptide patents.
